Suppr超能文献

细胞色素 P450 酶作为人类疾病的药物靶点。

Cytochrome P450 Enzymes as Drug Targets in Human Disease.

机构信息

Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee

出版信息

Drug Metab Dispos. 2024 May 16;52(6):493-497. doi: 10.1124/dmd.123.001431.

Abstract

Although the mention of cytochrome P450 (P450) inhibition usually brings to mind unwanted variability in pharmacokinetics, in several cases P450s are good targets for inhibition. These P450s are essential, but in certain disease states, it is desirable to reduce the concentrations of their products. Most of the attention to date has been with human P450s 5A1, 11A1, 11B1, 11B2, 17A1, 19A1, and 51A1. In some of those cases, there are multiple drugs in use, e.g., exemestane, letrozole, and anastrozole with P450 19A1, the steroid aromatase target in breast cancer. There are also several targets that are less developed, e.g., P450s 2A6, 8B1, 4A11, 24A1, 26A1, and 26B1. SIGNIFICANCE STATEMENT: The selective inhibition of certain cytochrome P450s that have major physiological functions has been shown to be very efficacious in certain human diseases. In several cases, the search for better drugs continues.

摘要

虽然提到细胞色素 P450(P450)抑制通常会让人联想到药代动力学的不必要变异性,但在某些情况下,P450 是抑制的良好靶点。这些 P450 是必需的,但在某些疾病状态下,降低其产物的浓度是可取的。迄今为止,大多数关注的焦点都集中在人类 P450 5A1、11A1、11B1、11B2、17A1、19A1 和 51A1 上。在其中一些情况下,有多种药物在使用,例如,与 P450 19A1 一起使用的 exemestane、letrozole 和 anastrozole,这是乳腺癌中甾体芳香酶的靶标。还有一些靶标开发得较少,例如 P450 2A6、8B1、4A11、24A1、26A1 和 26B1。重要性声明:选择性抑制某些具有主要生理功能的细胞色素 P450 已被证明在某些人类疾病中非常有效。在某些情况下,人们仍在寻找更好的药物。

相似文献

1
Cytochrome P450 Enzymes as Drug Targets in Human Disease.
Drug Metab Dispos. 2024 May 16;52(6):493-497. doi: 10.1124/dmd.123.001431.
2
Updates on Mechanisms of Cytochrome P450 Catalysis of Complex Steroid Oxidations.
Int J Mol Sci. 2024 Aug 20;25(16):9020. doi: 10.3390/ijms25169020.
3
Cloning and tissue expression of cytochrome P450 2S1, 4V2, 7A1, 7B1, 8B1, 24A1, 26A1, 26C1, 27A1, 39A1, and 51A1 in marmosets.
Drug Metab Pharmacokinet. 2020 Apr;35(2):244-247. doi: 10.1016/j.dmpk.2019.11.008. Epub 2019 Dec 26.
4
Cytochrome Binds Tightly to Several Human Cytochrome P450 Enzymes.
Drug Metab Dispos. 2021 Oct;49(10):902-909. doi: 10.1124/dmd.121.000475. Epub 2021 Jul 30.
6
Human cytochrome P450 enzymes bind drugs and other substrates mainly through conformational-selection modes.
J Biol Chem. 2019 Jul 12;294(28):10928-10941. doi: 10.1074/jbc.RA119.009305. Epub 2019 May 30.
8
The use of aromatase inhibitors in boys with short stature: what to know before prescribing?
Arch Endocrinol Metab. 2017 Jul-Aug;61(4):391-397. doi: 10.1590/2359-3997000000284.
9
A suite of activity-based probes for human cytochrome P450 enzymes.
J Am Chem Soc. 2009 Aug 5;131(30):10692-700. doi: 10.1021/ja9037609.
10
In vitro cytochrome P450-mediated metabolism of exemestane.
Drug Metab Dispos. 2011 Jan;39(1):98-105. doi: 10.1124/dmd.110.032276. Epub 2010 Sep 28.

引用本文的文献

1
Unmasking Conformationally Adaptable Lipids as Drug Receptors.
J Med Chem. 2025 Aug 28;68(16):16912-16920. doi: 10.1021/acs.jmedchem.5c01035. Epub 2025 Aug 11.
3
Severe cutaneous adverse reactions associated with second-generation androgen receptor antagonists in prostate cancer patients.
PLoS One. 2025 Jun 10;20(6):e0325448. doi: 10.1371/journal.pone.0325448. eCollection 2025.
5
Brain Cytochrome P450: Navigating Neurological Health and Metabolic Regulation.
J Xenobiot. 2025 Mar 14;15(2):44. doi: 10.3390/jox15020044.
6
Integrated Pharmacogenetic Signature for the Prediction of Prostatic Neoplasms in Men With Metabolic Disorders.
Cancer Genomics Proteomics. 2025 Mar-Apr;22(2):285-305. doi: 10.21873/cgp.20502.
9
Breaking the Barriers of Therapy Resistance: Harnessing Ferroptosis for Effective Hepatocellular Carcinoma Therapy.
J Hepatocell Carcinoma. 2024 Jul 2;11:1265-1278. doi: 10.2147/JHC.S469449. eCollection 2024.
10
Steroidogenic cytochrome P450 enzymes as drug target.
Toxicol Res. 2024 Apr 22;40(3):325-333. doi: 10.1007/s43188-024-00237-0. eCollection 2024 Jul.

本文引用的文献

2
Non-steroidal CYP17A1 Inhibitors: Discovery and Assessment.
J Med Chem. 2023 May 25;66(10):6542-6566. doi: 10.1021/acs.jmedchem.3c00442. Epub 2023 May 16.
3
Cytochrome P450 and Other Drug-Metabolizing Enzymes As Therapeutic Targets.
Drug Metab Dispos. 2023 Aug;51(8):936-949. doi: 10.1124/dmd.122.001011. Epub 2023 Apr 11.
4
Pyridine-containing substrate analogs are restricted from accessing the human cytochrome P450 8B1 active site by tryptophan 281.
J Biol Chem. 2023 Apr;299(4):103032. doi: 10.1016/j.jbc.2023.103032. Epub 2023 Feb 17.
6
First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis.
Mol Cancer Ther. 2022 Dec 2;21(12):1765-1776. doi: 10.1158/1535-7163.MCT-22-0115.
7
The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancer.
Bioorg Med Chem Lett. 2022 Nov 1;75:128951. doi: 10.1016/j.bmcl.2022.128951. Epub 2022 Aug 27.
8
Nirmatrelvir Plus Ritonavir: First Approval.
Drugs. 2022 Apr;82(5):585-591. doi: 10.1007/s40265-022-01692-5.
9
Stepwise binding of inhibitors to human cytochrome P450 17A1 and rapid kinetics of inhibition of androgen biosynthesis.
J Biol Chem. 2021 Aug;297(2):100969. doi: 10.1016/j.jbc.2021.100969. Epub 2021 Jul 15.
10
U.S. FDA Approved Drugs from 2015-June 2020: A Perspective.
J Med Chem. 2021 Mar 11;64(5):2339-2381. doi: 10.1021/acs.jmedchem.0c01786. Epub 2021 Feb 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验